MovDisordV3, PascalFrancis, Corpus, bibRecord, 002471

Clinical and economic analysis of spa therapy in Parkinson's disease

Identifieur interne : 002471 ( PascalFrancis/Corpus ); précédent : 002470; suivant : 002472

Clinical and economic analysis of spa therapy in Parkinson's disease

Auteurs : Christine Brefel-Courbon ; Karine Desboeuf ; Claire Thalamas ; Monique Galitzky ; Jean-Michel Senard ; Olivier Rascol ; Jean-Louis Montastruc

Source :

Movement disorders [ 0885-3185 ] ; 2003.

RBID : Pascal:03-0379960

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Cure thermale, Qualité vie, Analyse économique, Essai clinique, Efficacité traitement, Homme.

English descriptors

KwdEn :
- Clinical trial, Economic analysis, Human, Parkinson disease, Quality of life, Thermal cure, Treatment efficiency.

Abstract

The effectiveness of spa therapy in the management of patients with Parkinson's disease (PD) has never been evaluated. This is assessed in this pilot study. A prospective, randomized, cross-over, controlled study was conducted in 31 PD patients who underwent a 20-week spa period, including spa therapy for 3 weeks, and a 20-week non-spa period. Effectiveness was assessed using quality of life scales (PDQ-39 and SF-36), motor scale (UPDRS) and psychological questionnaire (GHQ-28), at baseline and at 4 (T4) and at 20 weeks (T20). Direct medical costs (radiological and laboratory tests, physician fees, drug therapy, and ancillary care) were recorded over each 20-week period. At T4, spa therapy improved significantly several dimensions of PDQ-39 and SF-36, part IV of the UPDRS, and GHQ-28. At T20, no difference in any parameter was found. The mean direct medical cost over 20 weeks (?1,328 ± 167; £776 ± 97 per patient) in the spa period was slightly but significantly reduced in comparison with that of the non-spa period (?1380 ± 523; £807 ± 306 per patient). This cost-effectiveness analysis suggests that spa therapy is more effective and less expensive than conventional treatment alone and could be beneficial in the management of PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 18`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Clinical and economic analysis of spa therapy in Parkinson's disease`
A11	`01`	`1`		`@1 BREFEL-COURBON (Christine)`
A11	`02`	`1`		`@1 DESBOEUF (Karine)`
A11	`03`	`1`		`@1 THALAMAS (Claire)`
A11	`04`	`1`		`@1 GALITZKY (Monique)`
A11	`05`	`1`		`@1 SENARD (Jean-Michel)`
A11	`06`	`1`		`@1 RASCOL (Olivier)`
A11	`07`	`1`		`@1 MONTASTRUC (Jean-Louis)`
A14	`01`			`@1 Service de Pharmacologie Clinique and Service d'Hydrologie et de Climatologie Médicales, Laboratoire de Médecine Thermale, University Hospital @2 Toulouse @3 FRA @Z 1 aut. @Z 2 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut.`
A14	`02`			`@1 Centre d'Investigation Clinique, Purpan Hospital @2 Toulouse @3 FRA @Z 3 aut. @Z 4 aut. @Z 6 aut.`
A20				`@1 578-584`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000118200090140`
A44				`@0 0000 @1 © 2003 INIST-CNRS. All rights reserved.`
A45				`@0 23 ref.`
A47	`01`	`1`		`@0 03-0379960`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The effectiveness of spa therapy in the management of patients with Parkinson's disease (PD) has never been evaluated. This is assessed in this pilot study. A prospective, randomized, cross-over, controlled study was conducted in 31 PD patients who underwent a 20-week spa period, including spa therapy for 3 weeks, and a 20-week non-spa period. Effectiveness was assessed using quality of life scales (PDQ-39 and SF-36), motor scale (UPDRS) and psychological questionnaire (GHQ-28), at baseline and at 4 (T4) and at 20 weeks (T20). Direct medical costs (radiological and laboratory tests, physician fees, drug therapy, and ancillary care) were recorded over each 20-week period. At T4, spa therapy improved significantly several dimensions of PDQ-39 and SF-36, part IV of the UPDRS, and GHQ-28. At T20, no difference in any parameter was found. The mean direct medical cost over 20 weeks (?1,328 ± 167; £776 ± 97 per patient) in the spa period was slightly but significantly reduced in comparison with that of the non-spa period (?1380 ± 523; £807 ± 306 per patient). This cost-effectiveness analysis suggests that spa therapy is more effective and less expensive than conventional treatment alone and could be beneficial in the management of PD.
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Cure thermale @5 04`
C03	`02`	`X`	`ENG`	`@0 Thermal cure @5 04`
C03	`02`	`X`	`SPA`	`@0 Cura termal @5 04`
C03	`03`	`X`	`FRE`	`@0 Qualité vie @5 07`
C03	`03`	`X`	`ENG`	`@0 Quality of life @5 07`
C03	`03`	`X`	`SPA`	`@0 Calidad vida @5 07`
C03	`04`	`X`	`FRE`	`@0 Analyse économique @5 10`
C03	`04`	`X`	`ENG`	`@0 Economic analysis @5 10`
C03	`04`	`X`	`SPA`	`@0 Análisis económico @5 10`
C03	`05`	`X`	`FRE`	`@0 Essai clinique @5 16`
C03	`05`	`X`	`ENG`	`@0 Clinical trial @5 16`
C03	`05`	`X`	`SPA`	`@0 Ensayo clínico @5 16`
C03	`06`	`X`	`FRE`	`@0 Efficacité traitement @5 17`
C03	`06`	`X`	`ENG`	`@0 Treatment efficiency @5 17`
C03	`06`	`X`	`SPA`	`@0 Eficacia tratamiento @5 17`
C03	`07`	`X`	`FRE`	`@0 Homme @5 20`
C03	`07`	`X`	`ENG`	`@0 Human @5 20`
C03	`07`	`X`	`SPA`	`@0 Hombre @5 20`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
N21				`@1 265`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 03-0379960 INIST
ET :	Clinical and economic analysis of spa therapy in Parkinson's disease
AU :	BREFEL-COURBON (Christine); DESBOEUF (Karine); THALAMAS (Claire); GALITZKY (Monique); SENARD (Jean-Michel); RASCOL (Olivier); MONTASTRUC (Jean-Louis)
AF :	Service de Pharmacologie Clinique and Service d'Hydrologie et de Climatologie Médicales, Laboratoire de Médecine Thermale, University Hospital/Toulouse/France (1 aut., 2 aut., 5 aut., 6 aut., 7 aut.); Centre d'Investigation Clinique, Purpan Hospital/Toulouse/France (3 aut., 4 aut., 6 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2003; Vol. 18; No. 5; Pp. 578-584; Bibl. 23 ref.
LA :	Anglais
EA :	The effectiveness of spa therapy in the management of patients with Parkinson's disease (PD) has never been evaluated. This is assessed in this pilot study. A prospective, randomized, cross-over, controlled study was conducted in 31 PD patients who underwent a 20-week spa period, including spa therapy for 3 weeks, and a 20-week non-spa period. Effectiveness was assessed using quality of life scales (PDQ-39 and SF-36), motor scale (UPDRS) and psychological questionnaire (GHQ-28), at baseline and at 4 (T4) and at 20 weeks (T20). Direct medical costs (radiological and laboratory tests, physician fees, drug therapy, and ancillary care) were recorded over each 20-week period. At T4, spa therapy improved significantly several dimensions of PDQ-39 and SF-36, part IV of the UPDRS, and GHQ-28. At T20, no difference in any parameter was found. The mean direct medical cost over 20 weeks (?1,328 ± 167; £776 ± 97 per patient) in the spa period was slightly but significantly reduced in comparison with that of the non-spa period (?1380 ± 523; £807 ± 306 per patient). This cost-effectiveness analysis suggests that spa therapy is more effective and less expensive than conventional treatment alone and could be beneficial in the management of PD.
CC :	002B17G
FD :	Parkinson maladie; Cure thermale; Qualité vie; Analyse économique; Essai clinique; Efficacité traitement; Homme
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED :	Parkinson disease; Thermal cure; Quality of life; Economic analysis; Clinical trial; Treatment efficiency; Human
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
SD :	Parkinson enfermedad; Cura termal; Calidad vida; Análisis económico; Ensayo clínico; Eficacia tratamiento; Hombre
LO :	INIST-20953.354000118200090140
ID :	03-0379960

Links to Exploration step

Pascal:03-0379960

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Clinical and economic analysis of spa therapy in Parkinson's disease</title>
<author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique and Service d'Hydrologie et de Climatologie Médicales, Laboratoire de Médecine Thermale, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Desboeuf, Karine" sort="Desboeuf, Karine" uniqKey="Desboeuf K" first="Karine" last="Desboeuf">Karine Desboeuf</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique and Service d'Hydrologie et de Climatologie Médicales, Laboratoire de Médecine Thermale, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name>
<affiliation><inist:fA14 i1="02"><s1>Centre d'Investigation Clinique, Purpan Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Galitzky, Monique" sort="Galitzky, Monique" uniqKey="Galitzky M" first="Monique" last="Galitzky">Monique Galitzky</name>
<affiliation><inist:fA14 i1="02"><s1>Centre d'Investigation Clinique, Purpan Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique and Service d'Hydrologie et de Climatologie Médicales, Laboratoire de Médecine Thermale, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique and Service d'Hydrologie et de Climatologie Médicales, Laboratoire de Médecine Thermale, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Centre d'Investigation Clinique, Purpan Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique and Service d'Hydrologie et de Climatologie Médicales, Laboratoire de Médecine Thermale, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0379960</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0379960 INIST</idno>
<idno type="RBID">Pascal:03-0379960</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002471</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Clinical and economic analysis of spa therapy in Parkinson's disease</title>
<author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique and Service d'Hydrologie et de Climatologie Médicales, Laboratoire de Médecine Thermale, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Desboeuf, Karine" sort="Desboeuf, Karine" uniqKey="Desboeuf K" first="Karine" last="Desboeuf">Karine Desboeuf</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique and Service d'Hydrologie et de Climatologie Médicales, Laboratoire de Médecine Thermale, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name>
<affiliation><inist:fA14 i1="02"><s1>Centre d'Investigation Clinique, Purpan Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Galitzky, Monique" sort="Galitzky, Monique" uniqKey="Galitzky M" first="Monique" last="Galitzky">Monique Galitzky</name>
<affiliation><inist:fA14 i1="02"><s1>Centre d'Investigation Clinique, Purpan Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique and Service d'Hydrologie et de Climatologie Médicales, Laboratoire de Médecine Thermale, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique and Service d'Hydrologie et de Climatologie Médicales, Laboratoire de Médecine Thermale, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Centre d'Investigation Clinique, Purpan Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Pharmacologie Clinique and Service d'Hydrologie et de Climatologie Médicales, Laboratoire de Médecine Thermale, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical trial</term>
<term>Economic analysis</term>
<term>Human</term>
<term>Parkinson disease</term>
<term>Quality of life</term>
<term>Thermal cure</term>
<term>Treatment efficiency</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Cure thermale</term>
<term>Qualité vie</term>
<term>Analyse économique</term>
<term>Essai clinique</term>
<term>Efficacité traitement</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The effectiveness of spa therapy in the management of patients with Parkinson's disease (PD) has never been evaluated. This is assessed in this pilot study. A prospective, randomized, cross-over, controlled study was conducted in 31 PD patients who underwent a 20-week spa period, including spa therapy for 3 weeks, and a 20-week non-spa period. Effectiveness was assessed using quality of life scales (PDQ-39 and SF-36), motor scale (UPDRS) and psychological questionnaire (GHQ-28), at baseline and at 4 (T4) and at 20 weeks (T20). Direct medical costs (radiological and laboratory tests, physician fees, drug therapy, and ancillary care) were recorded over each 20-week period. At T4, spa therapy improved significantly several dimensions of PDQ-39 and SF-36, part IV of the UPDRS, and GHQ-28. At T20, no difference in any parameter was found. The mean direct medical cost over 20 weeks (?1,328 ± 167; £776 ± 97 per patient) in the spa period was slightly but significantly reduced in comparison with that of the non-spa period (?1380 ± 523; £807 ± 306 per patient). This cost-effectiveness analysis suggests that spa therapy is more effective and less expensive than conventional treatment alone and could be beneficial in the management of PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>18</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Clinical and economic analysis of spa therapy in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BREFEL-COURBON (Christine)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DESBOEUF (Karine)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>THALAMAS (Claire)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GALITZKY (Monique)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SENARD (Jean-Michel)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>RASCOL (Olivier)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MONTASTRUC (Jean-Louis)</s1>
</fA11>
<fA14 i1="01"><s1>Service de Pharmacologie Clinique and Service d'Hydrologie et de Climatologie Médicales, Laboratoire de Médecine Thermale, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Centre d'Investigation Clinique, Purpan Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>578-584</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000118200090140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>23 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0379960</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The effectiveness of spa therapy in the management of patients with Parkinson's disease (PD) has never been evaluated. This is assessed in this pilot study. A prospective, randomized, cross-over, controlled study was conducted in 31 PD patients who underwent a 20-week spa period, including spa therapy for 3 weeks, and a 20-week non-spa period. Effectiveness was assessed using quality of life scales (PDQ-39 and SF-36), motor scale (UPDRS) and psychological questionnaire (GHQ-28), at baseline and at 4 (T4) and at 20 weeks (T20). Direct medical costs (radiological and laboratory tests, physician fees, drug therapy, and ancillary care) were recorded over each 20-week period. At T4, spa therapy improved significantly several dimensions of PDQ-39 and SF-36, part IV of the UPDRS, and GHQ-28. At T20, no difference in any parameter was found. The mean direct medical cost over 20 weeks (?1,328 ± 167; £776 ± 97 per patient) in the spa period was slightly but significantly reduced in comparison with that of the non-spa period (?1380 ± 523; £807 ± 306 per patient). This cost-effectiveness analysis suggests that spa therapy is more effective and less expensive than conventional treatment alone and could be beneficial in the management of PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Cure thermale</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Thermal cure</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Cura termal</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Qualité vie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Quality of life</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Calidad vida</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Analyse économique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Economic analysis</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Análisis económico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Efficacité traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment efficiency</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Eficacia tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>265</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 03-0379960 INIST</NO>
<ET>Clinical and economic analysis of spa therapy in Parkinson's disease</ET>
<AU>BREFEL-COURBON (Christine); DESBOEUF (Karine); THALAMAS (Claire); GALITZKY (Monique); SENARD (Jean-Michel); RASCOL (Olivier); MONTASTRUC (Jean-Louis)</AU>
<AF>Service de Pharmacologie Clinique and Service d'Hydrologie et de Climatologie Médicales, Laboratoire de Médecine Thermale, University Hospital/Toulouse/France (1 aut., 2 aut., 5 aut., 6 aut., 7 aut.); Centre d'Investigation Clinique, Purpan Hospital/Toulouse/France (3 aut., 4 aut., 6 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2003; Vol. 18; No. 5; Pp. 578-584; Bibl. 23 ref.</SO>
<LA>Anglais</LA>
<EA>The effectiveness of spa therapy in the management of patients with Parkinson's disease (PD) has never been evaluated. This is assessed in this pilot study. A prospective, randomized, cross-over, controlled study was conducted in 31 PD patients who underwent a 20-week spa period, including spa therapy for 3 weeks, and a 20-week non-spa period. Effectiveness was assessed using quality of life scales (PDQ-39 and SF-36), motor scale (UPDRS) and psychological questionnaire (GHQ-28), at baseline and at 4 (T4) and at 20 weeks (T20). Direct medical costs (radiological and laboratory tests, physician fees, drug therapy, and ancillary care) were recorded over each 20-week period. At T4, spa therapy improved significantly several dimensions of PDQ-39 and SF-36, part IV of the UPDRS, and GHQ-28. At T20, no difference in any parameter was found. The mean direct medical cost over 20 weeks (?1,328 ± 167; £776 ± 97 per patient) in the spa period was slightly but significantly reduced in comparison with that of the non-spa period (?1380 ± 523; £807 ± 306 per patient). This cost-effectiveness analysis suggests that spa therapy is more effective and less expensive than conventional treatment alone and could be beneficial in the management of PD.</EA>
<CC>002B17G</CC>
<FD>Parkinson maladie; Cure thermale; Qualité vie; Analyse économique; Essai clinique; Efficacité traitement; Homme</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Thermal cure; Quality of life; Economic analysis; Clinical trial; Treatment efficiency; Human</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<SD>Parkinson enfermedad; Cura termal; Calidad vida; Análisis económico; Ensayo clínico; Eficacia tratamiento; Hombre</SD>
<LO>INIST-20953.354000118200090140</LO>
<ID>03-0379960</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002471 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002471 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:03-0379960
   |texte=   Clinical and economic analysis of spa therapy in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Clinical and economic analysis of spa therapy in Parkinson's disease

Clinical and economic analysis of spa therapy in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri